TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518/TU2670' from NMPA in China
Details : TU2670 is an orally active non-peptide GnRH antagonist currently undergoing a Phase 2a clinical study in the EU for the treatment of moderate to severe pain associated with endometriosis.
Product Name : TU2670
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 07, 2023
Lead Product(s) : Mirodenafil
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AriBio Co., Ltd. Announces the Successful Completion of Their End of Phase 2 Meeting With the USFDA
Details : Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity, also has demonstrated notable effects against amyloid plaques and tau proteins via autophagy activation.
Product Name : AR1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 05, 2022
Lead Product(s) : Mirodenafil
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mirodenafil
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Cleveland Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Positive Phase II trial reported for AR1001, the results confirmed the possibility of developing a unique oral disease-modifying treatment for AD that improves cognitive function. The Company will complete Phase III clinical trials of AR1001 within the n...
Product Name : AR1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2021
Lead Product(s) : Mirodenafil
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Cleveland Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The paper is titled 'Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's already receiving donepezil and contains an analysis of the overall data from the Phase II clinical trial for Alzheimer's disease conducted in Korea.
Product Name : GV1001
Product Type : Peptide
Upfront Cash : Inapplicable
March 30, 2021
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GemVax & Kael Reports Further Positive Data from GV1001 Phase II Alzheimer's Disease Trial
Details : GemVax's GV1001 Phase II trial evaluated the safety and efficacy of subcutaneous injection of GV1001 0.56 mg or 1.12 mg for six months in patients with moderate-to-severe Alzheimer's disease already receiving donepezil for more than three months, at 12 m...
Product Name : GV1001
Product Type : Peptide
Upfront Cash : Inapplicable
November 23, 2020
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mirodenafil
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : SK Chemicals
Deal Size : Inapplicable
Deal Type : Inapplicable
AriBio Announces Completion of Enrollment in Phase 2 Alzheimer’s Study with AR1001
Details : AriBio completed enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease.
Product Name : AR1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 17, 2020
Lead Product(s) : Mirodenafil
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : SK Chemicals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The pivotal decision is based on an encouraging recent analysis of results from a Phase II trial of GV1001, completed last year in Korea and if granted would apply to a second Phase IIb trial in the US now planned for early 2021.
Product Name : GV1001
Product Type : Peptide
Upfront Cash : Inapplicable
June 10, 2020
Lead Product(s) : Tertomotide
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bio-Pharm Solutions Expands from Epilepsy to Neurodegenerative Diseases Aiming for IPO
Details : The oral medication for Infantile spasms (IS) is in phase 2 clinical trials in Korea and the US, and the IV medication for Status epilepticus (SE) is in phase 1 clinical trials in the US.
Product Name : JBPOS0101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 26, 2020